Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
Ormation Disclosure Statement (IDS) Filed
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE	Application Number Filing Date		10713808 2003-11-14	
	First Named Inventor	Dave	S.B. Hoon	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1642	
(Not for Submission under or of it 1.00)	Examiner Name	Sean	E. Aeder	
	Attorney Docket Numb	er	JWCI 0035 PUSP	

	U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	)ate	of cited Document		Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wisl	h to ac	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P.	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where les or Relev	
	1										
If you wisl	h to ac	dd additional U.S. Publis	shed Ap	plication	citation	n information p	lease click the Add	button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document	∍ or V F	vhere Rele	or Relevant	T5
	1										
If you wisl	h to ac	dd additional Foreign Pa	tent Do	cument	citation	information pl	ease click the Add	button	Add		
			NON	I-PATEN	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the au (book, magazine, journ publisher, city and/or of	nal, seria	al, symp	osium,	catalog, etc), c					<b>T</b> 5

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10713808		
Filing Date		2003-11-14		
First Named Inventor Dave		S.B. Hoon		
Art Unit		1642		
Examiner Name Sean		E. Aeder		
Attorney Docket Number		JWCI 0035 PUSP		

1	ZEHENTNER ET AL., Mammaglobin as a Novel Breast Cancer Biomarker: Multigene Reverse Transcription-PCR Assay and Sandwich ELISA," Clinical Chemistry, 50: 2069-76, 2004	
2	SCHULTZ ET AL., "A MAGE-A3 Peptide Presented by HLA-DP4 is Recognized on Tumor Cells by CD4+ Cytolytic T Lymphocytes," Cancer Research, 60: 6272-5, 2000	
3	SCHUSTER, R. ET AL., "Quantitative Real-Time RT-PCR for Detection of Disseminated Tumor Cells in Peripheral Blood of Patients with Colorectal Cancer Using Different mRNA Markers," Ins. J. Cancer, v. 108, n. 2, pp. 219-227, 1-10-2004	
4	SOONG ET AL., "Quantitative Reverse Transcription-Polymerase Chain Reaction Detection of Cytokeratin 20 in Noncolorectal Lymph Nodes," Clinical Cancer Res., v. 7, 3423-3429, 2001	
5	SORENSEN, B.S. ET AL., "Quantification of Melanoma Cell-specific MART-I mRNA in Peripheral Blood by a Calibrated Competitive Reverse Transcription-PCR," Clinical Chemistry 46:12, 9-26-2000, pp. 1923-1928	
6	STATHOPOULOU ET AL., "Real Time Quantification of CK-19 mRNA-Positive Cells in Peripheral Blood of Breast Cancer Patients Using the Lightcycler System," Clinical Cancer Research, 9: 5145-5151, 2003	
7	TABACK ET AL., "Detection of Occult Metastatic Breast Cancer Cells in Blood by a Multimolecular Marker Assay: Correlation with Clinical Stage of Disease," Cancer Research, 61: 8845-8850, 2001	
8	TAKEUCHI ET AL., "Expression of Differentiation Melanoma-Associated Antigen Genes is Associated with Favorable Disease Outcome in Advanced-Stage Melanomas," Cancer Research, 63: 441-8, 2003	
9	TAKEUCHI ET AL., "Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients," J. Clinical Oncology, 22: 2671-80, 2004	
10	VOIT ET AL., "Molecular Staging in Stage II and III Melanoma Patients and its Effect on Long-Term Survival," J. Clinical Oncology, 23: 1218-1227, 2005	
11	WASCHER ET AL., "Molecular Tumor Markers in the Blood: Early Prediction of Disease Outcome in Melanoma Patients Treated with a Melanoma Vaccine," J. Clinical Oncology, 21: 2558-63, 2003	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10713808		
Filing Date		2003-11-14		
First Named Inventor Dave		S.B. Hoon		
Art Unit		1642		
Examiner Name Sean		E. Aeder		
Attorney Docket Number		JWCI 0035 PUSP		

12	WASCHER ET AL., "Stannicalcin-1: A Novel Molecular Blood and Bone Marrow Marker for Human Breast Cancer," Clinical Cancer Res., 9: 1427-35, 2003	
13	BALCH ET AL., "Efficacy of an Elective Regional Lymph Node Dissection of 1 to 4 mm Thick Melanomas for Patients 60 Years of Age and Younger," Ann. Surg. 1996; 224:255-63	
14	BALCH ET AL., "A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (stage I) Melanoma Treated in Alabama, USA and New South Wales, Australia, Ann. Surg. 196:677-684, 1982	
15	CASCINELLI ET AL., "Immediate or Delayed Dissection of Regional Nodes in Patients with Melanoma of the Trunk: a Randomized Trial," WHO Melanoma Programme. Lancet, 1998; 351:796-6	
16	CLEGG, R.M., "Fluorescence Energy Transfer.," Curr. Opin. Biotech, 6: 103-110, 1995	
17	COCHRAN ET AL., "Occult Melanoma in Lymph Nodes Detected by Antiserum to S-100 Protein," Int. J. Cancer, 1984; 34:159-63	
18	JEMAL ET AL., Cancer Statistics 2002, CA Cancer J. Clin., 52: 23-47, 2002	
19	KAWAKAMI ET AL., "Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with In Vivo Tumor Rejection," Proc. Natl. Acad. Sci., USA, 91: 6458-6462, 1994	
20	MORTON ET AL., "Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy with a New Polyvalent Melanoma Vaccine," Ann. Surg. 1992; 216:463-82	
21	RIGEL ET AL., "The Incidence of Malignant Melanoma in the United States: Issues as we Approach the 21st Century," J. Am. Acad. Dermotol., 34: 839-847, 1996	
22	SHIVERS ET AL., "Molecular Staging of Malignant Melanoma: Correlation with Clinical Outcome," JAMA 1998; 280:1410-5	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10713808		
Filing Date		2003-11-14		
First Named Inventor Dave		S.B. Hoon		
Art Unit		1642		
Examiner Name Sean		E. Aeder		
Attorney Docket Number		JWCI 0035 PUSP		

	23	Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma, J. Clin. Oncol., 16: 3635-3648, 2001					
	SPECHT, K. ET AL., "Quantitative Gene Expression Anaylsis in Microdissected Archival Tissue by Real-Time RT-PCR," J. Mol. Med. 78: B27, 2000 (Abstract)						
If you wish to add additional non-patent literature document citation information please click the Add button Add							
		EXAMINER SIGNATURE					
Examiner	Examiner Signature Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
<sup>1</sup> See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.							